<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="13386">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02049307</url>
  </required_header>
  <id_info>
    <org_study_id>PCC-007</org_study_id>
    <nct_id>NCT02049307</nct_id>
  </id_info>
  <brief_title>Losartan to Reduce Inflammation and Fibrosis Endpoints in HIV Trial</brief_title>
  <acronym>LIFE-HIV</acronym>
  <official_title>Losartan to Reduce Inflammation and Fibrosis Endpoints in HIV Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Minneapolis Medical Research Foundation</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Minneapolis Medical Research Foundation</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the potential effectiveness of losartan (100mg
      daily) for reducing inflammation and improving immune recovery.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>August 2014</start_date>
  <primary_completion_date type="Anticipated">July 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Interleukin 6 (IL-6) plasma levels</measure>
    <time_frame>12 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Change in plasma IL-6 levels from baseline over 12 months</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cluster of differentiation 4 (CD4+) cell count</measure>
    <time_frame>12 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Change in CD4+ cell count from baseline over 12 months</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Inflammation</condition>
  <condition>Fibrosis</condition>
  <arm_group>
    <arm_group_label>Treatment</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Losartan 100mg daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Matching placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Losartan 100mg daily</intervention_name>
    <arm_group_label>Treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Matching placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  HIV infection (verified by previous positive antibody or detectable HIV RNA level)

          -  Age &gt; 50 years

          -  Receiving continuous ART for &gt;= 2 years (regimen changes &gt; 6 months prior to
                enrollment are allowed)

          -  HIV RNA level &lt; 200 copies/mL for &gt;= 1 year (1 measure &gt;= 200 allowed if also &lt; 1000
             and preceded and followed by values &lt; 200 copies/mL)

          -  Blood CD4+ T-cell count &lt; 600 cells/mm cubed

          -  Systolic blood pressure &gt; 120 mmHg (mean value if &gt;= 2 measures obtained)

          -  Estimated glomerular filtration rate (GFR )&gt; 30 mL/min/1.73 m squared

          -  Do not anticipate starting or stopping statin or aspirin therapy during the study

        Exclusion Criteria:

          -  Pregnancy or breastfeeding

          -  A contra-indication to taking an angiotensin receptor blocker (ARB) (e.g., cirrhosis,
             prior angioedema with angiotensin-converting enzyme inhibitor (ACE-I), or use of drug
             with potential drug-interaction [e.g., rifaximin])

          -  A clinical indication for ARB or ACE-I therapy (e.g., cardiovascular disease (CVD),
             stroke, or diabetes mellitus (DM))

          -  Current treatment with ARB or medication with overlapping mechanism (e.g., ACE-I or
             aldosterone antagonist)

          -  Current treatment with immunomodulatory drugs within the past 6 months

          -  Current hepatitis treatments (e.g., interferon, ribavirin) within the past 6 months

          -  Serum potassium &gt; 5.0 millimoles per liter (mmol/L) within 3 months of entry

          -  Invasive cancer in the prior year or receiving cancer treatment (not including
             carcinoma-in-situ or basal cell cancer of the skin)

          -  Cirrhosis or end-stage liver disease

          -  Rheumatologic or chronic inflammatory disease (e.g., systematic lupus erythematous,
             psoriasis, rheumatoid arthritis, vasculitis, sarcoidosis, Crohn's disease)
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jason Baker, M.D.</last_name>
    <phone>612-873-2700</phone>
    <email>baker@umn.edu</email>
  </overall_contact>
  <verification_date>March 2014</verification_date>
  <lastchanged_date>March 24, 2014</lastchanged_date>
  <firstreceived_date>January 27, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Minneapolis Medical Research Foundation</investigator_affiliation>
    <investigator_full_name>Jason Baker</investigator_full_name>
    <investigator_title>Protocol Chair</investigator_title>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>No</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Fibrosis</mesh_term>
    <mesh_term>Inflammation</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Losartan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
